Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma | Zendy

Ajai Chari | Zendy; Dan T. Vogl | Zendy; Maria Gavriatopoulou | Zendy; Ajay K. Nooka | Zendy; Andrew J. Yee | Zendy; Carol Ann Huff | Zendy; Philippe Moreau | Zendy; David Dingli | Zendy; Craig E. Cole | Zendy; Sagar Lonial | Zendy; Meletios Α. Dimopoulos | Zendy; A. Keith Stewart | Zendy; Joshua Richter | Zendy; Ravi Vij | Zendy; Sascha A. Tuchman | Zendy; Marc S. Raab | Zendy; Katja Weisel | Zendy; Michel Delforge | Zendy; Robert F. Cornell | Zendy; David Kaminetzky | Zendy; James E. Hoffman | Zendy; Luciano J. Costa | Zendy; Terri L. Parker | Zendy; Moshe Levy | Zendy; Martin Schreder | Zendy; Nathalie Meuleman | Zendy; Laurent Frenzel | Zendy; Mohamad Mohty | Zendy; Sylvain Choquet | Zendy; Gary J. Schiller | Zendy; Raymond L. Comenzo | Zendy; Monika Engelhardt | Zendy; Thomas Illmer | Zendy; Philip Vlummens | Zendy; Chantal Doyen | Zendy; Thierry Façon | Zendy; Lionel Karlin | Zendy; Aurore Perrot | Zendy; Klaus Podar | Zendy; Michael Kauffman | Zendy; Sharon Shacham | Zendy; Lingling Li | Zendy; Shijie Tang | Zendy; Carla Picklesimer | Zendy; JeanRichard SaintMartin | Zendy; Marsha Crochiere | Zendy; Hua Chang | Zendy; Samir Parekh | Zendy; Yosef Landesman | Zendy; Jatin J. Shah | Zendy; Paul G. Richardson | Zendy; Sundar Jagannath | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Author(s) -

Ajai Chari,

Dan T. Vogl,

Maria Gavriatopoulou,

Ajay K. Nooka,

Andrew J. Yee,

Carol Ann Huff,

Philippe Moreau,

David Dingli,

Craig E. Cole,

Sagar Lonial,

Meletios Α. Dimopoulos,

A. Keith Stewart,

Joshua Richter,

Ravi Vij,

Sascha A. Tuchman,

Marc S. Raab,

Katja Weisel,

Michel Delforge,

Robert F. Cornell,

David Kaminetzky,

James E. Hoffman,

Luciano J. Costa,

Terri L. Parker,

Moshe Levy,

Martin Schreder,

Nathalie Meuleman,

Laurent Frenzel,

Mohamad Mohty,

Sylvain Choquet,

Gary J. Schiller,

Raymond L. Comenzo,

Monika Engelhardt,

Thomas Illmer,

Philip Vlummens,

Chantal Doyen,

Thierry Façon,

Lionel Karlin,

Aurore Perrot,

Klaus Podar,

Michael Kauffman,

Sharon Shacham,

Lingling Li,

Shijie Tang,

Carla Picklesimer,

JeanRichard SaintMartin,

Marsha Crochiere,

Hua Chang,

Samir Parekh,

Yosef Landesman,

Jatin J. Shah,

Paul G. Richardson,

Sundar Jagannath

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1903455

Subject(s) - daratumumab , pomalidomide , carfilzomib , lenalidomide , refractory (planetary science) , population , dexamethasone , multiple myeloma , medicine , bortezomib , oncology , clinical endpoint , gastroenterology , pharmacology , clinical trial , biology , environmental health , astrobiology

Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma that is refractory to current therapeutic options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research